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The synthesis and in vivo evaluation of 11C-labeled uric acid ([11C]1), a potential 
imaging agent for the diagnosis of urate-related life-style diseases, was performed using 
positron emission tomography (PET) image analysis. First, the synthesis of [11C]1 was 
achieved by reacting 5,6-diaminouracil (2) with 11C-labeled phosgene ([11C]COCl2). The 
radiochemical yield of [11C]1 was 37±7% (decay-corrected based on [11C]COCl2) with 
specific radioactivities of 96-152 GBq/μmol at the end of synthesis (n = 6). The average time 
of radiosynthesis from the end of bombardment, including formulation, was about 30 min 
with >98% radiochemical purity. Second, the synthetic approach to [11C]1 was optimized 
using 5,6-diaminouracil sulfate (3) with [11C]COCl2 in the presence of 
1,8-bis(dimethylamino)naphthalene. [11C]1 was synthesized in 36±6% radiochemical yield, 
89-142 GBq/μmol of specific radioactivities, and 98% radiochemical purity by this method (n 
= 5). This allowed the synthesis of [11C]1 to be carried out repeatedly and the radiochemical 
yield, specific radioactivities, average time of synthesis, and radiochemical purity of [11C]1 
were similar to those obtained using 2. PET studies in rats showed large differences in the 
accumulation of radioligand in the limbs under normal and hyperuricemic conditions. Thus, 
an efficient and convenient automated synthesis of [11C]1 has been developed, and 
preliminary PET evaluation of [11C]1 confirmed the increased accumulation of radioactivity 






PET: Positron Emission Tomography  
DMPU: N,N'-dimethylpropyleneurea 






High serum uric acid level, or hyperuricemia, is a hallmark of gout, and lead to the 
crystallization of monosodium urate in joints and the formation of urinary tract calculi. In 
hyperuricemia, approximately 80% of patients also suffer from some type of lifestyle-related 
disease such as hypertension, cardiovascular disease, obesity and dyslipidemia; however, the 
clinical significance of these conditions remains controversial [1]. Baseline laboratory tests 
for gout include urinalysis, serum uric acid measurements and other biochemical 
examinations of blood. Although hyperuricemia is a risk factor for the development of gout 
and other disorders, the relationship between serum uric acid levels and the pathogenesis of 
these disorders remains unclear. Other diagnostic methods for gout include the examination of 
the presence of polymorphonuclear leukocytes and intracellular monosodium urate crystals in 
synovial fluid aspirated from an inflamed joint, but other disorders can sometimes mimic gout. 
Thus, measurement of tissue concentrations of uric acid is essential for the early diagnosis of 
gout and other urate-related life-style diseases. 
Positron emission tomography (PET) is a molecular and functional imaging 
technique that allows highly sensitive, noninvasive, quantitative and repetitive visualization of 
biological functions in living animals in vivo with biologically active compounds labeled with 
short-lived positron emitting radionuclides (11C, 13N, 15O and 18F) that do not affect the 
biochemical and physiochemical characteristics [2-8]. Generally, the tracer doses used in PET 




µg/dose [9]. Thus, PET has recently been applied to human microdose studies at early stages 
of drug and biomarker development [10]. The development of a quantitative PET imaging 
method with radiolabeled uric acid would enable the noninvasive assessment of uric acid 
accumulation in diseased tissue and may also demonstrate the feasibility of PET imaging 
analysis for the early diagnosis of gout and relevant diseases. 
In vivo molecular imaging with small animal models bridges the gap between 
laboratory research and human clinical studies. In rodents, uric acid is the product of purine 
metabolism, and is subsequently degraded by the hepatic enzyme uricase into a water-soluble 
product (allantoin) [11]. In humans, uric acid is the end product of purine metabolism due to 
the lack of uricase [12,13]. Several groups have reported that hyperuricemia can be induced in 
rats by administering the uricase inhibitor oxonic acid [14]. Oxonic acid-treated rats can 
therefore serve as a useful animal model for investigating the pathogenesis of gout, as well as 
a number of other uric acid-related disorders. 
Herein, we report the first synthesis of 11C-labeled uric acid ([11C]1, Fig. 1) using 
[11C]COCl2. Subsequently, we compared the accumulation of the radioligand in the tissues of 
hyperuricemic rats with that in normal rats by small-animal PET using [11C]1. 
The synthesis of PET molecular probes labeled with short-lived radionuclides 
requires a very rapid and simple labeling process. We selected 11C-labeled phosgene 




introduction of a [11C]carbonyl group and is very useful for synthesis of heterocyclic 
compounds [15-17]. This approach involves efficient construction of cyclic [11C]urea moiety, 
which requires reliable preparation of [11C]COCl2 and uses 5,6-diaminouracil (2) as a starting 
material (Scheme 1). 
Thus, 2 was reacted with [11C]COCl2 to give [11C]1 in N,N'-dimethylpropyleneurea 
(DMPU) solution at 100°C for 2 min. [11C]COCl2 was synthesized from [11C]methane via 
[11C]CCl4 according to a previously reported method [18,19]. [11C]Methane was produced 
using a CYPRIS HM-12S cyclotron (Sumitomo Heavy Industries) by the 14N(p,α)11C nuclear 
reaction in N2 containing H2 (10%) on an aluminum target. Bombardment was carried out 
with a 30 μA beam of 12 MeV protons for 10 min. The [11C]methane and Cl2 gas mixture was 
passed through a quartz U-tube at 560°C to give [11C]CCl4. The [11C]CCl4 was next passed 
through the oxidation tube of a Kitagawa gas detection tube system at room temperature at a 
flow rate of 50 mL/min to afford [11C]COCl2. The [11C]COCl2 was bubbled into a DMPU 
solution [20] (150 μL) containing 2 (1.0 mg, 7.04 μmol) and N,N-diisopropylethylamine 
(DIPEA) [21] (9.10 mg, 70.4 μmol) at -10°C for 2 min. The mixture was then heated at 100°C 
for 2 min to form [11C]1. After cooling, the reaction mixture was diluted with phosphate 
buffer and injected into a preparative HPLC system for purification of [11C]1 (column: 
Unison UK-C18, 7 mm, Imtakt, 10 × 250 mm ; solvents and conditions: 10 mM Phosphate 




10-fold with saline prior to the injection. The yield of [11C]1 was 1314 ± 226 MBq at the end 
of synthesis (n = 6) (Scheme 1). The decay corrected radiochemical yield of [11C]1 was 
37±7% based on [11C]COCl2 [22]. The overall radiosynthesis time was ca. 30 min from the 
end of bombardment.  
The synthesized [11C]1 was identified by co-chromatography with authentic uric acid 
and found to be radiochemically homogeneous by HPLC. Figure 2 shows HPLC 
chromatograms before and after purification. These chromatograms show that [11C]1 was 
produced as the major radioactive peak in the reaction mixture (Fig. 2A), and the 
radiochemical purity of [11C]1 was ca. 98% after purification (Fig. 2B). The specific activity 
of [11C]1 was 96-152 GBq/μmol at the end of synthesis. Although the synthesis of [11C]1 
from 2 was successful with high RI, and chemical yield was sufficient for use a PET 
molecular probe, there are some practical disadvantages in using 2, such as its high cost, 
difficulty in handling and its chemical instability for long-term storage. 
In order to overcome these problems, synthesis was modified, using 
5,6-diaminouracil sulfate (3) as a starting material (Scheme 2), which is commercially 
available at lower cost and is easier to handle than 2. As 3 did not react with [11C]COCl2 
without neutralization, appropriate labeling conditions were investigated using several bases 
for the neutralization in situ of 3 in labeling reaction (Table 1). It was shown that, 




found to be ineffective in this reaction (entries 3 and 5). On the other hand, a small amount of 
[11C]1 was obtained when 18-crown-6 was added to improve reactivity of KN(SiMe3)2 (entry 
6), but had no effect in the case of t-BuOK (entry 4). Next, we investigated the use of the 
highly basic but very weakly nucleophilic (non-nucleophilic proton trapping) bases 
1,8-bis(dimethylamino)naphthalene and 1,8-bis(N,N,N',N'-tetramethylguanidino)naphthalene, 
which are well-known proton sponges (entries 7 and 8). [11C]1 was synthesized in 36±6% 
radiochemical yield, 89-142 GBq/μmol of specific radioactivities, and 98% radiochemical 
purity (entry 7, n = 5). The labeling reaction with proton sponge was conducted under the 
same conditions [23] as used previously with 2, and [11C]1 was reproducibly obtained with 
similar yield and specific radioactivities as obtained with 2. Based on this experimental data, 
it is clear that a proton sponge is effective in this labeling reaction using 3. 
Subsequently, we performed PET studies for [11C]1 in anesthetized rats [24-27] 
under normal or hyperuricemic conditions, in which rats were premedicated with potassium 
oxonate (250 mg/kg, i.p.) [11,14]. After intravenous bolus injection of [11C]1 (22-30 MBq per 
animal) via the tail vein, whole body scans were performed with 180-s duration for 1 bed pass, 
in addition to blood sampling via the femoral vein. Data were sorted into dynamic sinograms 
for each bed pass. Emission data were reconstructed by Fourier Rebinning and maximum 
likelihood expectation maximization. Regions of interest (ROIs) were delineated for the limbs, 




Zurich, Switzerland). Radioactivity in the ROIs was estimated by percent of total radioactivity 
at each frame. 
The maximum intensity projection PET images in the whole body following 
administration of [11C]1 to rats under normal or hyperuricemic conditions are shown in Fig. 3. 
The radioactivity was mainly eliminated via renal excretion in both rats. The radioactivity in 
the limbs was clearly identifiable under hyperuricemic conditions, as compared with normal 
conditions. The distribution of radioactivity in the limbs under hyperuricemic conditions was 
2.6-fold higher than that under normal conditions (Fig. 4A). On the other hand, the 
radioactivity in the blood at 60 min (Fig. 4B) and that remained in the whole body at 65-70 
min following administration of [11C]1 (Fig. 4C), in which the radioactivity excreted via renal 
excretion was excluded, were 1.6-fold and 1.5-fold higher under hyperuricemic conditions 
than under normal conditions, respectively, but the difference did not reach the statistical 
significance. Endogenous uric acid level in plasma under hyperuricemic conditions was 
12.7-fold higher than that under normal conditions (Fig. 4D). Representative 
radio-chromatograms of blood specimens showed that most of the radioactivity in the blood 
was derived from the soluble metabolite ([11C]allantoin) under normal conditions, whereas 
almost 100% of the radioactivity was present as the parent [11C]1 under hyperuricemic 




The ratios of total radioactivity in the blood under hyperuricemic and normal 
conditions (1.6-fold) are lower than those for the distribution of radioactivity in the limbs 
(2.6-fold). The radioactivity derived from [11C]1 in blood under hyperuricemic conditions, as 
calculated by radiometabolite analysis, was 0.570.16% of the injected dose, whereas that 
under normal conditions was below the limit of detection. On the other hand, the ratios of 
endogenous uric acid levels in plasma under hyperuricemic and normal conditions (12.7-fold) 
were much higher than those for the distribution of radioactivity in the limbs. These results 
suggest that the radioactivity of [11C]1 accumulates in areas of low temperature such as joints, 
which can be difficult to determine by analysis of blood uric acid levels and endogenous uric 
acid levels in plasma. The overall transport mechanism of [11C]1 between blood and the joint 
region has been unknown, but it has been reported that uric acid is a substrate for GLUT9 
(SLC2A9), which is expressed in chondrocytes [28]. The uptake of [11C]1 into the joint may 
also provide the information about the function of GLUT9 in chondrocytes. 
The present PET studies in rats with [11C]1 clearly suggest the feasibility of clinical 
diagnosis of gout and the accumulation of urate in joints. As the PET image analysis with 
[11C]1 focus on the tissue distribution and renal excretion of uric acid, but not the production 
of uric acid, it is also possible that PET study with [11C]1 is useful for the in vivo evaluation 




uric acid. This may be confirmed using quantitative PET image analysis of the abdominal 
area in future studies. 
In conclusion, an efficient repeatable, convenient and automated synthesis method 
for [11C]uric acid has been developed. Preliminary PET evaluation of [11C]uric acid was 
performed in a rat model of hyperuricemia, and clearly showed the potential of [11C]uric acid 
as a PET molecular probe for the diagnosis of hyperuricemia, gout and other urate-related 
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Scheme 1. Radiosynthesis of [11C]1. Reagents and conditions, (a) DIPEA (10 eq), DMPU, 
100 °C, 2 min.; Cyclotron irradiation time; 10 min (30 μA); Total synthetic time; 30 min. 









Figure 2. HPLC chromatograms of [11C]1. (A): before purification (B): after purification. UV 
absorbance, 290 nm. UV absorption at around 2 min is caused by solvents present in the 

























Figure 3. Representative whole body maximum intensity projection (MIP) image in rats 
captured at 65-70 min after administration of [11C]1. (A: normal condition; B: hyperuricemic 
condition). Arrows indicate the region of limbs in which higher accumulation of the 












Figure 4. Comparison of (A) radioactivity in limbs at 65-70 min, (B) radioactivity in blood 
sampled at 60 min, (C) radioactivity remained in the body as determined by subtraction of the 
radioactivity excreted via renal excretion from that detected in whole body region at 65-70 
min following administration of [11C]1,and (D) endogenous uric acid level in plasma in rats 
between normal condition and hyperuricemic condition. Each bar represents the mean ± S.D. 
(n=3-4 for (A)-(C); n=9 for (D)). The statistically significant differences were observed 

















































































































































































































































































































Figure 5. Representative HPLC radiochromatograms of [11C]1 and its metabolite in blood 
specimens. Blood specimens at 30 min of rats under normal condition (A) and hyperuricemic 
condition (B) were subjected to radiometric HPLC analysis. The identification of the retention 
time of 1 and hydrophilic metabolite (allantoin) were performed using authentic standard of 
each compound. 
 
 
 
 
 
